HealthDay News — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Feb. 27 in Practical Radiation Oncology, evidence-based recommendations are ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

The event raises money for Mater Hospital’s Chicks in Pink campaign, helping provide support services, new equipment and fund vital breast cancer research for the more than 20,000 women who will ...

A brave Birmingham schoolboy has been diagnosed with a rare cancer after a routine eye test revealed the wicked disease. Huge Aston Villa fan Lewis Jukes, just 10, was having issues with his vision ...

Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment Because of a lack of evidence-based ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...